

Regatul Unit-Bristol: Servicii de patologie
OJ S 21/2020 30/01/2020
Anunț de transparență ex ante voluntară
Servicii

Temei juridic:
Directiva 2014/24/UE

Secțiunea I: Autoritatea/entitatea contractantă

I.1. Denumire și adrese

Denumire oficială: North Bristol NHS Trust
Adresă: Southmead Road, Bristol
Localitate: Bristol
Cod NUTS: UKK11 Bristol, City of
Cod poștal: BS10 5NB
Țară: Regatul Unit
Persoană de contact: Martin Strawson
E-mail: martin.strawson@UH Bristol.nhs.uk
Telefon: +44 1173420815
Adresă (adrese) internet:
Adresa principală: <https://www.nbt.nhs.uk/>

I.4. Tipul autorității contractante

Alt tip: NHS trust

I.5. Activitate principală

Sănătate

Secțiunea II: Obiect

II.1. Obiectul achiziției

II.1.1. Titlu

Procurement of a Large Throughput DNA Sequencer
Număr de referință: BWPCCL001501

II.1.2. Cod CPV principal

85111800 Servicii de patologie

II.1.3. Tipul contractului

Servicii

II.1.4. Descriere succintă

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Informații privind loturile

Contractul este împărțit în loturi: nu

II.1.7. Valoarea totală a achiziției

Valoare fără TVA: 779 625,00 GBP

II.2. Descriere

II.2.2. Cod(uri) CPV suplimentar(e)

85111000 Servicii spitalicești

II.2.3. Locul de executare

Cod NUTS: UKK11 Bristol, City of

II.2.4. Descrierea achiziției publice

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Criterii de atribuire

Criteriu privind calitatea - Nume: Quality / Pondere: 90

Prețul - Pondere: 10

II.2.11.

Informații privind opțiunile

Opțiuni: nu

II.2.13. Informații despre fondurile Uniunii Europene

Achiziția se referă la un proiect și/sau program finanțat din fonduri ale Uniunii Europene: nu

II.2.14. Informații suplimentare

Secțiunea IV: Procedură

IV.1. Descriere

IV.1.1. Tipul procedurii

Atribuirea unui contract fără publicarea prealabilă a unei invitații la procedura concurențială de ofertare în Jurnalul Oficial al Uniunii Europene în cazurile enumerate mai jos

- Achiziția nu se încadrează în domeniul de aplicare al directivei

Explicație:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Informații privind acordul-cadru

IV.1.8. Informații despre Acordul privind achizițiile publice (AAP)

Achiziția intră sub incidența Acordului privind achizițiile publice: nu

IV.2. Informații administrative

Secțiunea V: Atribuirea contractului/concesiunii

Titlu:

Procurement of Large High Throughput DNA Sequencer

V.2. Atribuirea contractului/concesiunii

V.2.1. Data deciziei de atribuire a contractului

28/01/2020

V.2.2. Informații privind ofertele

Contractul a fost atribuit unui grup de operatori economici: nu

V.2.3. Numele și adresa contractantului/concesionarului

Denumire oficială: Illumina Cambridge Ltd

Adresă: Chesterford Research Park, Little Chesterford

Localitate: Saffron Walden

Cod NUTS: UKI London

Cod poștal: CB10 1XL

Țară: Regatul Unit

Contractantul/concesionarul va fi un IMM: da

V.2.4. Informații privind valoarea contractului/lotului/concesiunii

Valoarea totală a contractului/lotului/concesiunii: 779 625,00 GBP

V.2.5. Informații privind subcontractarea

Secțiunea VI: Informații complementare

VI.3. Informații suplimentare

VI.4. Proceduri de contestare

VI.4.1. Organismul de soluționare a contestațiilor

Denumire oficială: Bristol and Weston Purchasing Consortium

Adresă: Level 3, Whitefriars, Lewins Mead

Localitate: Bristol

Cod poștal: BS1 2NT

Țară: Regatul Unit

E-mail: martin.strawson@UHBristol.nhs.uk

VI.4.2. Organismul competent pentru procedurile de mediere

Denumire oficială: Bristol and Weston Purchasing Consortium

Adresă: Level 3, Whitefriars, Lewins Mead

Localitate: Bristol

Cod poștal: BS1 2NT

Țară: Regatul Unit

VI.4.4. Serviciul de la care se pot obține informații privind procedura de contestare

Denumire oficială: Bristol and Weston Purchasing Consortium

Adresă: Level 3, Whitefriars, Lewins Mead

Localitate: Bristol

Cod poștal: BS1 2NT

Țară: Regatul Unit

VI.5. Data expedierii prezentului anunț

28/01/2020